Compare Stocks

Date Range: 

 Calithera BiosciencesObsEvaSCYNEXISMarker TherapeuticsEnlivex Therapeutics
SymbolNASDAQ:CALANASDAQ:OBSVNASDAQ:SCYXNASDAQ:MRKRNASDAQ:ENLV
Price Information
Current Price$2.09$2.80$6.87$2.35$10.04
52 Week RangeBuyHoldBuyBuyBuy
MarketRank™
Overall Score1.81.41.41.51.4
Analysis Score3.43.23.53.43.5
Community Score2.82.32.82.53.4
Dividend Score0.00.00.00.00.0
Ownership Score1.70.80.81.70.0
Earnings & Valuation Score1.30.60.00.00.0
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuyBuy
Consensus Price Target$5.20$11.80$30.29$8.67$33.00
% Upside from Price Target148.80% upside321.43% upside340.84% upside268.79% upside228.69% upside
Trade Information
Market Cap$154.76 million$161.15 million$141.74 million$186.36 million$158.23 million
Beta1.770.992.161.271.14
Average Volume1,435,9024,695,241567,6682,899,517366,256
Sales & Book Value
Annual Revenue$22.25 millionN/A$120,000.00$210,000.00N/A
Price / Sales6.96N/A1,181.12887.44N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$2.24 per share$1.01 per share$1.32 per share$0.96 per share$1.09 per share
Price / Book0.93N/A5.202.45N/A
Profitability
Net Income$-89,860,000.00$-108,790,000.00$-53,710,000.00$-21,430,000.00$-9,380,000.00
EPS($1.90)($2.49)($8.10)($0.47)($1.11)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)-66.64%-256.23%-330.82%-68.00%-34.60%
Return on Assets (ROA)-56.60%-93.21%-64.53%-54.26%-28.47%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A1.14%1.39%N/A0.02%
Current Ratio7.07%2.06%3.89%5.03%7.23%
Quick Ratio7.07%2.06%3.89%5.03%7.23%
Ownership Information
Institutional Ownership Percentage73.99%52.74%36.92%29.42%2.39%
Insider Ownership Percentage11.90%N/A4.06%30.90%N/A
Miscellaneous
Employees9242384436
Shares Outstanding74.05 million57.55 million20.63 million79.30 million15.76 million
Next Earnings Date8/9/2021 (Estimated)8/5/2021 (Estimated)5/10/2021 (Estimated)5/12/2021 (Confirmed)5/17/2021 (Estimated)
OptionableOptionableNot OptionableOptionableOptionableNot Optionable
SourceHeadline
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Down 18.8% in AprilEnlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Down 18.8% in April
americanbankingnews.com - May 3 at 12:46 PM
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Expected to Post Earnings of -$0.21 Per ShareEnlivex Therapeutics Ltd. (NASDAQ:ENLV) Expected to Post Earnings of -$0.21 Per Share
americanbankingnews.com - May 2 at 12:10 PM
Enlivex Therapeutics shares are trading higher. Not seeing any company-specific news to justify the price action in the low-float stock.Enlivex Therapeutics shares are trading higher. Not seeing any company-specific news to justify the price action in the low-float stock.
benzinga.com - April 30 at 6:40 PM
Enlivex Therapeutics Ltd (ENLV)Enlivex Therapeutics Ltd (ENLV)
investing.com - April 28 at 8:17 AM
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Significant Drop in Short InterestEnlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Significant Drop in Short Interest
americanbankingnews.com - April 19 at 1:14 AM
Zacks: Brokerages Expect Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Will Post Earnings of -$0.21 Per ShareZacks: Brokerages Expect Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Will Post Earnings of -$0.21 Per Share
americanbankingnews.com - April 15 at 2:20 PM
ENLV May 2021 10.000 callENLV May 2021 10.000 call
ca.finance.yahoo.com - March 29 at 7:20 PM
ENLV Aug 2021 15.000 putENLV Aug 2021 15.000 put
ca.finance.yahoo.com - March 29 at 2:17 PM
Enlivex To Study Allocetra Combined With Checkpoint Inhibitors In Solid Tumor SettingsEnlivex To Study Allocetra Combined With Checkpoint Inhibitors In Solid Tumor Settings
benzinga.com - March 23 at 3:18 PM
Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect ...Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect ...
apnews.com - March 23 at 4:47 AM
Enlivex Therapeutics Ltd. (ENLV.TA)Enlivex Therapeutics Ltd. (ENLV.TA)
sg.finance.yahoo.com - March 22 at 1:45 PM
Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combination with Immune Checkpoint InhibitorsEnlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combination with Immune Checkpoint Inhibitors
finance.yahoo.com - March 22 at 8:45 AM
Enlivex Announces Upcoming Virtual Investor Conference ParticipationsEnlivex Announces Upcoming Virtual Investor Conference Participations
apnews.com - March 10 at 9:04 AM
Enlivex Announces Upcoming Virtual  Investor Conference ParticipationsEnlivex Announces Upcoming Virtual Investor Conference Participations
finance.yahoo.com - March 9 at 8:51 AM
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the use of Allocetra in Combination with CAR-T TherapiesEnlivex Receives Notice of Allowance for Japanese Patent Application Covering the use of Allocetra in Combination with CAR-T Therapies
finance.yahoo.com - March 8 at 9:09 AM
Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of ...Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of ...
apnews.com - March 2 at 9:05 AM
Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint InhibitorsEnlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors
finance.yahoo.com - March 1 at 8:56 AM
Enlivex Therapeutrics receives Chinese patent for Allocetra immunotherapyEnlivex Therapeutrics receives Chinese patent for Allocetra immunotherapy
pharmabiz.com - February 24 at 8:04 PM
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra ImmunotherapyEnlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy
wallstreet-online.de - February 22 at 2:47 PM
Enlivex Announces Exercise of Underwriters Option to Purchase Additional SharesEnlivex Announces Exercise of Underwriter's Option to Purchase Additional Shares
benzinga.com - February 19 at 8:05 AM
Enlivex Announces Exercise of Underwriter’s Option to Purchase Additional SharesEnlivex Announces Exercise of Underwriter’s Option to Purchase Additional Shares
finance.yahoo.com - February 18 at 9:53 AM
Enlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory ...Enlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory ...
apnews.com - February 17 at 8:24 AM
Enlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis and GvHD Using Allocetra ImmunotherapyEnlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis and GvHD Using Allocetra Immunotherapy
finance.yahoo.com - February 16 at 9:29 AM
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 ...Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 ...
apnews.com - February 13 at 12:13 AM
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary SharesEnlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
finance.yahoo.com - February 12 at 7:12 PM
DateCompanyBrokerageAction
1/5/2021Calithera BiosciencesCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price Target
1/5/2021Calithera BiosciencesSmith Barney CitigroupLower Price Target
1/5/2021Calithera BiosciencesHC WainwrightLower Price Target
1/5/2021Calithera BiosciencesSVB LeerinkDowngrade
6/2/2020Calithera BiosciencesWilliam BlairReiterated Rating
3/27/2020Calithera BiosciencesJefferies Financial GroupInitiated Coverage
1/12/2021ObsEvaWedbushReiterated Rating
11/9/2020ObsEvaJPMorgan Chase & Co.Downgrade
7/6/2020ObsEvaBMO Capital MarketsDowngrade
12/10/2019ObsEvaRoyal Bank of CanadaBoost Price Target
11/8/2019ObsEvaCredit Suisse GroupDowngrade
4/19/2021SCYNEXISAegisLower Price Target
2/17/2021SCYNEXISMaxim GroupBoost Price Target
1/22/2021SCYNEXISGuggenheimInitiated Coverage
1/5/2021SCYNEXISCantor FitzgeraldInitiated Coverage
8/11/2020SCYNEXISLADENBURG THALM/SH SHReiterated Rating
8/10/2020SCYNEXISNeedham & Company LLCInitiated Coverage
3/31/2021Marker TherapeuticsPiper SandlerInitiated Coverage
3/9/2021Marker TherapeuticsOppenheimerReiterated Rating
6/24/2020Marker TherapeuticsRoth CapitalReiterated Rating
6/24/2020Marker TherapeuticsJanney Montgomery ScottReiterated Rating
6/24/2020Marker TherapeuticsNomuraReiterated Rating
11/13/2019Marker TherapeuticsPiper Jaffray CompaniesLower Price Target
8/13/2019Marker TherapeuticsNomura SecuritiesReiterated Rating
3/29/2019Marker TherapeuticsWBB SecuritiesUpgrade
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.